Table 1 Annual mean (95Â % CI) number of SHEs in patients with T1 and T2 DM
Therapy | Average number of SHEs per patient per year | Probability of ≥1 SHE for a patient annually |
|---|---|---|
T1 | ||
Insulin pump | 0.168 (0.123–0.237) | 11.38 % (8.09 %–16.03 %) |
Basal-bolus (basal insulin analogue) | 0.472 (0.252–1.055) | 21.37 % (11.30 %–42.97 %) |
Basal-bolus (basal human insulin) | 1.084 (0.530–2.900) | 33.77 % (17.93 %–67.53 %) |
T2 | ||
BOT analogue | 0.113 (0.050–0.324) | 5.55 % (2.32 %–15.62 %) |
BOT human | 0.173 (0.072–0.600) | 7.95 % (3.18 %–26.35 %) |
Basal-bolus (basal insulin analogue) | 0.080 (0.027–0.456) | 4.78 % (1.21 %–27.04 %) |
Basal-bolus (basal human insulin) | 0.554 (0.157–7.534) | 31.40 % (7.44 %–99.64 %) |
Pre-mix insulin analogue | 0.092 (0.052–0.186) | 6.23 % (3.41 %–12.49 %) |
Pre-mix human insulin | 0.299 (0.137–0.868) | 12.43 % (5.87 %–31.85 %) |
Sulfonylureas | 0.045 (0.023–0.115) | 3.57 % (1.91 %–7.56 %) |